MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Moderna, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$226.89+8.88 (+4.07%)
Close on Oct 19, 2026
- Market cap
- $90.30B
- P/E (TTM)
- –
- Dividend yield
- –
Moderna, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $2.07B | $2.09B | $1.82B | $2.11B | $2.96B | $3.03B | $3.11B | $4.96B | $4.90B | $5.01B | $6.67B | $8.74B | 92.7% | -30.2% |
| COVID | $2.05B | $2.07B | $1.81B | $2.09B | $2.93B | $3.00B | $3.08B | $4.95B | $4.90B | – | $6.67B | – | 92.0% | -30.1% |
| Other revenue | $163.00M | $140.00M | $126.00M | $121.00M | $120.00M | $149.00M | $127.00M | $117.00M | $149.00M | $143.00M | $177.00M | $384.00M | 7.3% | +35.8% |
| Collaboration revenue (Note 5) | $28.00M | $17.00M | $13.00M | $25.00M | $46.00M | $49.00M | $48.00M | $55.00M | $57.00M | $73.00M | $83.00M | $353.00M | 1.3% | -39.1% |
| Grant revenue | $18.00M | $21.00M | $22.00M | $30.00M | $23.00M | $38.00M | $37.00M | – | – | – | – | – | 0.8% | -21.7% |
| RSV | $16.00M | $13.00M | $8.00M | $19.00M | $27.00M | $27.00M | $25.00M | $10.00M | $0 | – | $0 | – | 0.7% | -40.7% |
| Licensing and royalty revenue | – | – | – | $17.00M | $22.00M | $50.00M | $42.00M | $37.00M | $30.00M | $0 | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Moderna's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.